J9395 is a HCPCS Level II code used to report fulvestrant injection at 25 mg per billing unit. The code is associated with fulvestrant and is commonly used when billing for applicable fulvestrant administration in oncology settings. The key billing point to remember is that 1 unit is equal to 25 mg of fulvestrant. If this code is applied, therefore, a 500mg dose gets 20 billing units.
Fulvestrant is administered intramuscularly and the dosage regimen may impact on the amount reported on the claim. There should be a consensus between the medication, the dose, the NDC, the diagnosis, the administration service, the modifiers and the payer requirements. This guide provides the J9395 description, unit calculation, dosing for Faslodex, billing requirements, reimbursement considerations, documentation and common claim errors.
What Is the J9395 HCPCS Code?
J9395 is the HCPCS code for injection, fulvestrant, 25 mg. CMS materials identify the code with a 25 mg billing unit. Unlike miscellaneous drug codes, this code identifies the drug and establishes the dosage represented by each billing unit.
Code Summary
| Coding Element | Details |
|---|---|
| HCPCS code | J9395 |
| Drug | Fulvestrant |
| Brand associated with drug | Faslodex |
| Billing unit | 25 mg |
| Route | Intramuscular |
| Drug category | Antineoplastic/endocrine therapy |
| Dosage calculation | Administered mg ÷ 25 mg |
| NDC | Report according to payer requirements |
| Reimbursement | Payer and setting specific |
The 25 mg descriptor is critical when calculating units. Billing staff should not report one unit simply because one syringe, vial, or injection was used.
What Does J9395 Represent?
The HCPCS code for the injection, fulvestrant, 25mg. The code is listed on CMS materials with a 25 mg billing unit.
For example:
| Fulvestrant Dose | Units |
|---|---|
| 25 mg | 1 unit |
| 50 mg | 2 units |
| 125 mg | 5 units |
| 250 mg | 10 units |
| 500 mg | 20 units |
The calculation is:
Administered dose ÷ 25 mg = units
For a 500 mg dose:
500 mg ÷ 25 mg = 20 units
This calculation should be based on the documented administered dose. It should not be based solely on the number of syringes or packages supplied.
Fulvestrant and Faslodex Dosing
Faslodex is the brand name for fulvestrant. The FDA-approved labeling describes fulvestrant as an intramuscular injection supplied at a concentration of 50 mg/mL. The labeled standard dose is 500 mg, administered as two 5 mL injections, with loading doses followed by monthly administration.
The prescribing information describes the 500 mg regimen as administration on days 1, 15, and 29, followed by once-monthly administration. A 250 mg dose is described for certain patients with moderate hepatic impairment. This distinction matters for billing because the actual documented dose determines the quantity.
Common Dose-to-Unit Examples
| Documented Dose | Calculation | Units |
|---|---|---|
| 250 mg | 250 ÷ 25 | 10 |
| 500 mg | 500 ÷ 25 | 20 |
The treatment schedule does not change the HCPCS unit definition. Each claim should reflect the amount administered on that specific date of service.
How Many J9395 Units for 500 mg?
A 500 mg fulvestrant dose requires 20 units.
The calculation is:
500 mg ÷ 25 mg per unit = 20 units
This is one of the most important calculations for billing because the standard labeled Faslodex dose is 500 mg.
Billing 500 mg as one unit would underreport the drug quantity. Reporting 20 units correctly reflects the HCPCS descriptor. The claim should also contain documentation supporting the 500 mg dose and the actual administration.
How Many J9395 Units for 250 mg?
A 250 mg fulvestrant dose requires 10 units.
The calculation is:
250 mg ÷ 25 mg per unit = 10 units
The FDA labeling describes 250 mg as a recommended dose for patients with moderate hepatic impairment.
The medical record should support the reason for the documented dose. The claim quantity should then correspond to the administered amount.
Billing Guidelines
Correct billing starts with confirming the drug and dose. The claim should identify fulvestrant and report units based on the 25 mg HCPCS descriptor.
A typical billing review should verify:
- Correct HCPCS code
- Fulvestrant product administered
- Date of service
- Dose administered
- NDC when required
- Diagnosis code
- Administration service
- Applicable modifiers
- Waste information when applicable
- Payer coverage requirements
CMS states that providers should accurately report units of service and follow the applicable code descriptor and reporting instructions. The medication administration record should support the quantity submitted on the claim.
J9395 Units and Syringe Count
The count of syringes is not equal to HCPCS units. Fulvestrant comes in a strength of 50 mg per ml. A dosage of 500 mg requires two 5 mL injections; hence the number of actual injections is two, but there are 20 units of this code.
This creates an important distinction:
| Billing Concept | Standard 500 mg Example |
|---|---|
| Total dose | 500 mg |
| Concentration | 50 mg/mL |
| Injection volume | 10 mL total |
| Physical injections | 2 |
| J9395 units | 20 |
The claim should report the HCPCS quantity based on its descriptor, not the number of injection sites or syringes.
J9395 NDC Reporting
NDC reporting can help identify the specific fulvestrant product administered. The NDC should match the product documented in the medication record.
When a payer requires NDC reporting, verify:
- NDC number
- Manufacturer
- Product strength
- Package size
- NDC unit of measure
- Quantity administered
- NDC quantity
- HCPCS units
The NDC quantity and units are different concepts.
Units are based on 25 mg per HCPCS unit. NDC reporting follows the applicable product package and payer reporting methodology. This distinction helps prevent quantity mismatches during claim processing.
J9395 Diagnosis Coding
This code should be reported with diagnosis coding that accurately reflects the condition being treated. Fulvestrant is used in the treatment of certain hormone receptor-positive breast cancer situations. The FDA labeling identifies Faslodex for specified breast cancer indications. The ICD-10-CM code should come from the patient’s documented clinical condition rather than from the HCPCS code itself.
Depending on the documentation, coding considerations may include:
- Primary malignancy
- Breast site
- Laterality
- Metastatic disease
- Secondary malignancy
- Encounter-specific documentation
- Applicable treatment indication
The diagnosis should support medical necessity under the payer’s applicable policy.
J9395 Administration Coding
This code reports the drug. The administration service is evaluated separately. Because fulvestrant is administered intramuscularly, the applicable administration code should be selected based on the actual service performed and documented.
The record should support:
- Injection route
- Administration date
- Medication administered
- Injection site
- Provider or qualified professional
- Dose administered
- Any required administration details
The drug code itself does not automatically establish a separately payable administration service. Payer rules can also affect whether an administration service is separately reimbursed. Professional and facility claims may follow different payment methodologies.
J9395 Modifiers
This code does not automatically require a modifier. A modifier should only be reported when the documented circumstances and payer rules support it.
JW Modifier
The JW modifier is used to report applicable discarded amounts from a single-dose container or single-use package under Medicare policy. CMS states that applicable separately payable drugs with unused and discarded amounts should be reported with JW when the policy applies. The discarded amount should be supported by the medication record.
JZ Modifier
The JZ modifier indicates that there was no discarded amount from an applicable single-dose container or single-use package under Medicare’s applicable policy. Whether JW or JZ applies should be evaluated using the current Medicare requirements and the specific product packaging.
Other Modifiers
Other modifiers may apply depending on the claim circumstances, service setting, payer policy, or specific billing requirements. Modifiers should not be added simply because a claim contains this code. The underlying documentation should support each modifier reported.
J9395 and Drug Waste Billing
Waste reporting requires careful attention because the HCPCS unit represents 25 mg. The first step is to determine the total amount supplied. The second step is to identify the amount actually administered. The difference may represent discarded medication when the applicable policy allows or requires separate reporting. For Medicare claims, CMS provides specific JW and JZ requirements for applicable single-dose or single-use drug claims.
The medication record should clearly establish:
- Amount supplied
- Amount administered
- Amount discarded
- Container type
- Date of administration
- Applicable HCPCS units
- Applicable waste modifier
Do not automatically report the entire package as administered simply because the medication was opened.
J9395 Reimbursement
There is no single reimbursement amount that applies to every claim. Medicare Part B drug payment amounts can change by payment period. CMS publishes quarterly Medicare Part B drug payment limit files and NDC-HCPCS crosswalks for applicable drugs. For 2026, CMS has published multiple Part B payment files, including January, April, July, and October files. The applicable payment file depends on the date of service.
Reimbursement can also vary according to:
- Payer
- Date of service
- Place of service
- Provider type
- Medicare or commercial coverage
- Contractual fee schedule
- Drug payment methodology
- Claims processing rules
For this reason, a historical payment amount should not automatically be used as the current reimbursement rate.
J9395 Medicare Payment
Medicare payment for separately payable Part B drugs is generally based on applicable drug payment methodologies. CMS notes that most separately payable Part B drugs and biologicals use an Average Sales Price-based methodology, with many paid at ASP plus 6 percent.
However, the actual payment for a claim should be verified using the applicable CMS payment file for the date of service. The CMS payment limit file is updated periodically. The October 2026 file, for example, was published as a final file on September 17, 2026. Therefore, billing teams should avoid using an old reimbursement figure when calculating expected payment.
J9395 Reimbursement Calculation Example
Suppose a payer establishes a payment allowance of $X per unit for the applicable period.
For a 500 mg dose:
20 units × $X = applicable drug payment
The actual dollar amount should be obtained from the current payer or Medicare payment source.
This calculation illustrates why the unit count must be accurate. An incorrect quantity can directly affect the submitted drug charge and reimbursement calculation.
J9395 vs J9393 and J9394
Fulvestrant coding requires particular attention because CMS lists separate codes for certain fulvestrant products.
CMS identifies:
- J9395: Injection, fulvestrant, 25 mg
- J9393: Injection, fulvestrant, Teva, not therapeutically equivalent to J9395, 25 mg
- J9394: Injection, fulvestrant, Fresenius Kabi, not therapeutically equivalent to J9395, 25 mg
This distinction is important for product identification.
| HCPCS | Product Description | Unit |
|---|---|---|
| J9395 | Fulvestrant | 25 mg |
| J9393 | Fulvestrant, Teva | 25 mg |
| J9394 | Fulvestrant, Fresenius Kabi | 25 mg |
The correct code should correspond to the actual product administered and the code effective for the date of service. A billing team should therefore verify the manufacturer before automatically selecting this code for every fulvestrant claim.
Why J9395 Product Identification Matters
The existence of J9393 and J9394 makes product identification especially important. CMS created these manufacturer-specific fulvestrant codes with descriptors stating that they are not therapeutically equivalent to this code.
Before billing, review:
- Product name
- Manufacturer
- NDC
- Strength
- Date of service
- Applicable HCPCS code
- Payer requirements
This product-first approach helps prevent incorrect coding when different fulvestrant products are available.
J9395 Documentation Requirements
Complete documentation should support both the medication and the service.
Important records may include:
- Fulvestrant product name
- Manufacturer
- NDC
- Dose
- Concentration
- Route
- Injection sites
- Administration date
- Diagnosis
- Medical necessity
- Amount administered
- Amount discarded when applicable
- Authorization information
- Administration documentation
The documented dose should reconcile with the number of units submitted. For example, a 500 mg dose should support 20 units. A 250 mg dose should support 10 units.
Common J9395 Billing Errors
Reporting One Unit for 500 mg
J9395 represents 25 mg per unit. Therefore, a 500 mg dose requires 20 units.
Using Syringe Count as Units
Two fulvestrant injections do not mean two units of this code. The billing unit is based on 25 mg.
Ignoring Product Manufacturer
J9393 and J9394 represent specific fulvestrant products. The manufacturer’s product should be verified before choosing this code.
Reporting the Wrong NDC
The NDC should correspond to the actual product administered. A mismatched NDC can trigger claim edits or payment review.
Using an Outdated Payment Amount
Medicare drug payment files change periodically. The payment amount should be verified for the applicable date of service.
Reporting Unsupported Waste
Waste should be documented and reported according to applicable payer requirements. The medication record should support any JW claim line.
Omitting the Diagnosis
The diagnosis should establish the condition being treated. It should also meet the applicable payer’s medical necessity requirements.
Billing Unsupported Administration
A claim does not automatically establish a separately payable administration service. Documentation must support the administration code.
J9395 Denial Prevention
Preventing denials begins with accurate product identification.
Prior to submission of this code claim ensure that the actual fulvestrant product matches the HCPCS code. It is significant in this instance because the two numbers, J9393 and J9394 refer to certain formulations of fulvestrant.
Then check the dose and the units.
The estimated quantity of this code needed for a 500 mg dose is 20 units. The number of units needed for 250 mg dose is 10. Next, check the NDC, diagnosis documentation, administration documentation, modifiers, and payer requirements. Lastly, check reimbursement with the payment information for the date of service. The CMS posts revised Part B drug payment files on an annual basis.
J9395 Claim Submission Workflow
It is helpful to have a reliable process for verifying all the necessary details for claims prior to submission. This will reduce any errors concerning products, dosages, units, NDCs and billing coverage.
Step 1: Identify the Product
Verify the exact product of fulvestrant administered to the patient. Verify medication record, product name, strength, manufacturer, package information before billing.
Step 2: Verify the HCPCS Code
Determine if item J9395, J9393 or J9394 matches to the product provided. Before choosing the code, check the code description and payer rules.
Step 3: Confirm the Dose
Ensure that the dose is accurately administered using the medication administration history. Make sure that the correct dosage is documented for filing of bills.
Step 4: Calculate Units
Determine the appropriate units to bill based on the dose administered. To figure out the units for this code, divide the recorded amount of fulvestrant by 25.
Step 5: Verify the NDC
Verify NDC with a precise product administered to the patient. Acknowledge the NDC format and reporting requirements prior to claim submission.
Step 6: Review the Diagnosis
Review if the documented diagnosis is a basis for fulvestrant treatment. Make sure that the diagnosis matches with the medical record and the applicable coverage requirements from the payer.
Step 7: Review Administration
Ensure that the information regarding use of the drug is properly recorded in the medical record. Confirm route, date, dosage and if billing for separate administration permitted.
Step 8: Check Modifiers
Before submitting the claim, check any applicable modifiers, such as Review JW and JZ. Choose modifiers according to Drug Waste, Billing rules and Payer requirements.
Step 9: Check Coverage
Check active insurance, prior authorization, medical necessity, etc. with the payer. Clear up any approvals or coverage-related problems in advance of the bill.
Step 10: Verify Payment
Please refer to the current reimbursement rates for the date of service provided. Verify the expected payment is the same as the code, units, and payer rules.
Step 11: Submit and Monitor
Submit the claim after completing all checks. Examine the quantity, NDC, coverage, modifier and payment errors on payer responses and remittance details.
Conclusion
This code represents fulvestrant injection at 25 mg per billing unit. For the commonly used 500 mg dose, the correct quantity is 20 units. One of the most crucial billing steps is ensuring that the HCPCS quantity is matched with the documented dose. Medication records should be used to assist with dose, route, product, NDC, diagnosis and administration.
Product identification also needs special mention as CMS has listed both J9393 (Teva fulvestrant) and J9394 (Fresenius Kabi fulvestrant) at 25mg as not therapeutically equivalent to this code. Use applicable reimbursement methodology and date-specific payment information to check reimbursement. Medicare Part B drug payment files are updated periodically, and the amounts shown on older payments may not reflect actual reimbursement. Three essential steps in precise billing for this code are choosing the right product, determining the right units, and then providing full documentation to back it up.
